Sihuan Biotech announced that the company acquired 80% of the shares of Jilin Changyuan Pharmaceutical Co., Ltd. with 160 million yuan in cash. The transaction was reviewed and approved by the company's board of directors and the 3rd Extraordinary Shareholders' Meeting in 2026, and does not constitute a major asset restructuring or restructuring listing. At present, Changyuan Pharmaceutical has completed the registration procedure for industrial and commercial changes and obtained a renewed business license. The company holds 80% of its shares. Changyuan Pharmaceutical will be included in the scope of the company's consolidated statements and become the company's holding subsidiary.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.